Document is current

Article History

Received: 12 June 2025

Accepted: 7 August 2025

First Online: 4 September 2025

Conflict of interest

: J. Kappel, T. Müllner-Buscics, S. Riegler, N. Dominik, G. Kramer, C. Sebesta, P. Thöne, A.F. Stättermayer, L. Reider, M. Schoder, C. Klausenitz, R. Varga and F. Waneck declare that they have no competing interests. M. Hintersteininger received travel support from Roche. M. Trauner served as a speaker and/or consultant and/or advisory board member for Agomab, Albireo, BiomX, Chemomab, Falk, Boehringer Ingelheim, Bristol-Myers Squibb, Genfit, Gilead, Intercept, Ipsen, Janssen, Madrigal, Mirum, MSD, Novartis, Phenex, Pliant, ProQR Therapeuics, Regulus, and Shire, and received travel support from AbbVie, Falk Foundation, Gilead, and Intercept, as well as grants/research support from Albireo, Alnylam, Cymabay, Falk, Genfit, Gilead, Intercept, MSD, Takeda, and UltraGenyx. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid filed by the Medical Universities of Graz and Vienna. M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. T. Reiberger served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens, and W. L. Gore & Associates and received grants/research support from AbbVie, Boehringer Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Pliant, Philips, Siemens, and W. L. Gore & Associates as well as travel support from AbbVie, Boehringer Ingelheim, Gilead and Roche. L. Hartl received travel support from Abbvie.